http://www.hearingreview.com/reuters/en-usThu, 2 Jul 2009 19:01 ESTThu, 2 Jul 2009 19:01 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin003%2EhtmlNEW YORK (Reuters Health) - People who live alone in middle-age are significantly more likely to develop dementia and Alzheimer's disease in later life, compared with people who are married or cohabiting in mid-life, according to results of a study in the July 3 issue of BMJ Online First.Thu, 2 Jul 2009 19:01 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin003%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin017%2EhtmlNEW YORK (Reuters Health) - At recommended doses, anti-tumor necrosis factor (anti-TNF) treatments for rheumatoid arthritis do not increase the risk of serious adverse events, according to a report in the Annals of the Rheumatic Diseases for July.Thu, 2 Jul 2009 17:00 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin017%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin006%2EhtmlNEW YORK (Reuters Health) - Norovirus infection in preterm infants can follow widely varying clinical courses, according to findings published online June 2nd in BMC Research Notes.Thu, 2 Jul 2009 16:40 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin006%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin001%2EhtmlNEW YORK (Reuters Health) - Specific hepatitis B virus (HBV) mutations are associated with development of hepatocellular carcinoma (HCC) and may help predict infected patients' risk for these tumors, according to a report published online July 2nd in the Journal of the National Cancer Institute.Thu, 2 Jul 2009 16:33 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin001%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin007%2EhtmlNEW YORK (Reuters Health) - Although more than 90% of patients taking ocular hypotensive medication felt confident about aspects of their eyedrop instillation technique, less than a third actually demonstrated adequate skills in a study reported in the June issue of Archives of Ophthalmology.Thu, 2 Jul 2009 16:30 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin007%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702inds018%2EhtmlLJUBLJANA (Reuters) - Slovenian drug company Krka's group sales were up 2 percent in the first half of 2009 at 477.9 million euros ($674 million), the company said on Thursday.Thu, 2 Jul 2009 16:01 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702inds018%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702manc002%2EhtmlBANGALORE (Reuters) - Outsourcing of healthcare services is expected to gain momentum as the prolonged slowdown forces U.S.-based government agencies and healthcare firms to cut spiraling costs and deal with a shortage in qualified personnel.Thu, 2 Jul 2009 16:00 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702manc002%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702inds011%2EhtmlGENEVA (Reuters) - Swiss biotech group Addex is looking for partners to help develop several of its drugs, aiming to preserve its cash position through current tough refinancing markets, its chief executive told Reuters.Thu, 2 Jul 2009 16:00 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702inds011%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702inds001%2EhtmlBOSTON (Reuters) - Johnson & Johnson has agreed to pay $1 billion for an 18.4 percent stake in Irish drugmaker Elan Corp, and will acquire a major stake in Elan's portfolio of experimental drugs to treat Alzheimer's disease.Thu, 2 Jul 2009 16:00 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702inds001%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702publ001%2EhtmlLONDON (Reuters) - Britain is projecting more than 100,000 new cases a day of the H1N1 flu by the end of August and will change the way it deals with the virus, the government said on Thursday.Thu, 2 Jul 2009 15:28 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702publ001%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702legi001%2EhtmlWASHINGTON (Reuters) - Key Senate Democrats said on Thursday the cost of their plan to overhaul the U.S. healthcare system has dropped to $611 billion over a decade, a figure they hope will help draw wider bipartisan support in Congress.Thu, 2 Jul 2009 15:23 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702legi001%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin019%2EhtmlNEW YORK (Reuters Health) - Although factors such as diet and alcohol consumption do not seem to affect the risk of myelodysplastic syndromes (MDS), tobacco use and body mass index (BMI) are associated with these conditions, researchers report in the June 15th issue of the American Journal of Epidemiology.Thu, 2 Jul 2009 15:16 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin019%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin014%2EhtmlNEW YORK (Reuters Health) - People with white-coat hypertension (HTN) or masked HTN are at increased risk of developing sustained HTN, according to an article in the August issue of Hypertension.Thu, 2 Jul 2009 14:34 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin014%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin010%2EhtmlNEW YORK (Reuters Health) - Deep brain stimulation in the subthalamic nucleus (STN) or the globus pallidus interna (GPi) is associated with significant mood changes in patients with Parkinson's disease, according to a report in the May issue of the Annals of Neurology.Thu, 2 Jul 2009 13:46 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin010%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702drgd001%2EhtmlNEW YORK (Reuters Health) - ST-246, a novel orthopoxvirus egress inhibitor, protects nonhuman primates from challenges with smallpox or monkeypox virus, according to a report in the June Antimicrobial Agents and Chemotherapy.Thu, 2 Jul 2009 13:09 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702drgd001%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin005%2EhtmlNEW YORK (Reuters Health) - Use of statins and angiotensin converting-enzyme (ACE) inhibitors is associated with lower mortality after acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a report in the June 3rd Respiratory Research.Thu, 2 Jul 2009 12:34 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin005%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin020%2EhtmlNEW YORK (Reuters Health) - Long-term enzyme-replacement therapy (ERT) significantly reduces left ventricular (LV) hypertrophy, improves cardiac performance, and ameliorates clinical symptoms in patients with Anderson-Fabry disease.Thu, 2 Jul 2009 12:27 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin020%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702clin009%2EhtmlNEW YORK (Reuters Health) - Patients hospitalized with nursing home-acquired pneumonia have similar outcomes whether treated according to 2003 guidelines for community-acquired pneumonia or 2005 guidelines for healthcare-associated (HCA) pneumonia, according to a report in the June Journal of the American Geriatrics Society.Thu, 2 Jul 2009 12:25 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702clin009%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702rglt004%2EhtmlPARIS (Reuters) - Sanofi-Aventis won approval to sell Multaq (dronedarone) in the United States. The Food and Drug Administration (FDA) cleared Multaq twice-daily 400 mg tablets to reduce the risk of cardiovascular hospitalisation in patients with atrial fibrillation or atrial flutter, Sanofi said on Thursday.Thu, 2 Jul 2009 11:04 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702rglt004%2Ehtmlhttp://www.hearingreview.com/reuters_article.asp?id=20090702inds013%2EhtmlGENEVA (Reuters) - Swiss biotech group Addex is looking for partners to help develop several of its drugs, aiming to preserve its cash position through current tough refinancing markets, its chief executive told Reuters.Thu, 2 Jul 2009 11:00 ESThttp://www.hearingreview.com/reuters_article.asp?id=20090702inds013%2Ehtml